A compound called indole-3-propionic acid (IPA), naturally produced by gut bacteria, significantly reduced fatty liver disease in mice by activating a protective protein that blocks cellular stress and damage. According to Gram Research analysis of this 2026 study, IPA supplementation decreased liver fat accumulation, improved insulin resistance, and reduced liver cell death in high-fat diet-fed mice. However, human studies are needed before IPA can be recommended as a treatment.
Researchers discovered that a natural compound made by gut bacteria, called indole-3-propionic acid (IPA), may help prevent and treat fatty liver disease. In studies with mice, IPA reduced fat buildup in the liver, improved insulin resistance, and protected liver cells from damage. According to Gram Research analysis, this compound works by activating a protective protein in liver cells that reduces stress and cell death. While these findings are promising, the research is still in early stages using animal models, and human trials are needed before doctors can recommend IPA supplements for fatty liver disease treatment.
Key Statistics
A 2026 research article published in Hepatology Communications found that mice with fatty liver disease had significantly decreased serum and fecal IPA levels compared to healthy mice on normal diets.
In mouse studies, IPA supplementation reduced hepatic lipid accumulation and alleviated insulin resistance, liver damage, and steatosis development in high-fat diet-fed mice while restoring healthy gut bacteria composition.
The 2026 study identified that IPA works by promoting FMO2 expression, which inhibits the PERK/eIF2α/ATF4/CHOP signaling cascade, thereby reducing hepatocyte apoptosis and reactive oxygen species levels in fatty liver disease.
Research showed that IPA enhanced the interaction between FMO2 and PERK proteins, blocking phosphorylation of PERK and subsequently reducing endoplasmic reticulum stress in liver cells.
The Quick Take
- What they studied: Whether a compound made by gut bacteria called IPA could help treat fatty liver disease by reducing stress inside liver cells
- Who participated: Laboratory mice fed high-fat diets to develop fatty liver disease, plus liver cells studied in dishes. No human participants were involved in this research.
- Key finding: Mice that received IPA supplementation showed significantly reduced fat in their livers, improved insulin sensitivity, and less liver cell damage compared to untreated mice with fatty liver disease.
- What it means for you: This research suggests a potential new treatment approach for fatty liver disease, but it’s still in early stages. Don’t expect IPA supplements to be available as a medical treatment soon—human studies are needed first to confirm safety and effectiveness.
The Research Details
Scientists compared the gut bacteria and their products in healthy mice versus mice with fatty liver disease. They identified that IPA levels were much lower in sick mice. Then they tested whether giving IPA supplements to sick mice would help them recover. The researchers used multiple approaches: they measured changes in liver tissue, tracked how genes were turned on and off, and studied the process at the cellular level using liver cells in laboratory dishes.
The study examined how IPA works inside liver cells by looking at specific proteins and signaling pathways. When liver cells are stressed, they activate a chain reaction of proteins that can lead to cell death. The researchers discovered that IPA activates a protective protein called FMO2, which blocks this harmful chain reaction.
This is a mechanistic study, meaning it focuses on understanding the ‘how’ and ‘why’ rather than testing a treatment in humans. The researchers used advanced techniques like gene sequencing, protein analysis, and cell imaging to trace exactly how IPA protects liver cells.
Understanding the exact mechanism of how IPA works is crucial because it could lead to new drug development. Rather than just knowing that IPA helps, scientists now understand which proteins and pathways are involved, making it possible to design targeted treatments. This knowledge could eventually lead to medications that mimic IPA’s protective effects or enhance the body’s natural production of this compound.
This research was published in Hepatology Communications, a peer-reviewed scientific journal focused on liver disease research. The study used multiple complementary methods to verify findings, which strengthens confidence in the results. However, all experiments were conducted in mice and cell cultures—not humans. The study did not include a sample size specification in the published abstract, which is unusual. The research represents early-stage discovery work that requires follow-up human studies before clinical application.
What the Results Show
Mice fed high-fat diets developed fatty liver disease and showed dramatically reduced IPA levels in both their blood and stool compared to healthy mice eating normal food. When researchers gave IPA supplements to the sick mice, the results were striking: fat accumulation in the liver decreased significantly, insulin resistance improved, and overall liver damage was reduced.
The protective mechanism worked through a specific pathway inside liver cells. IPA activated a protein called FMO2, which then interacted with another protein called PERK. This interaction prevented PERK from triggering a stress response that normally leads to liver cell death. By blocking this stress cascade, IPA reduced both cell death and the production of harmful reactive oxygen species (molecules that damage cells).
The supplementation also helped restore the balance of gut bacteria, suggesting that IPA’s benefits extend beyond just the liver to improve overall gut health. This is important because a healthy gut microbiome is increasingly recognized as essential for preventing metabolic diseases.
Beyond the primary liver protection, IPA supplementation improved several related health markers. Insulin resistance—a key feature of metabolic dysfunction—improved in treated mice. The restoration of healthy gut bacteria composition suggests that IPA may have broader benefits for metabolic health. The reduction in reactive oxygen species indicates that IPA provides antioxidant protection, which could have implications for other diseases involving oxidative stress.
This research builds on growing evidence that gut bacteria and their metabolites play crucial roles in liver health. Previous studies showed that people with fatty liver disease have altered gut bacteria composition, but this study provides a specific mechanism explaining how one bacterial product—IPA—protects against the disease. The focus on the FMO2/PERK pathway is novel and offers a new therapeutic target that hadn’t been previously connected to IPA in liver disease.
The most significant limitation is that all experiments used mice and laboratory cell cultures—not humans. Mouse metabolism differs from human metabolism in important ways, so results may not translate directly. The study didn’t specify sample sizes for the animal experiments, making it difficult to assess statistical power. Additionally, this research focused on the mechanism of action rather than testing IPA as a practical treatment, so questions remain about optimal dosing, delivery methods, and long-term safety in humans. The study also didn’t compare IPA to existing fatty liver disease treatments, so its relative effectiveness is unknown.
The Bottom Line
Based on this research alone, there are no recommendations for patients to take IPA supplements. The evidence is strong for the biological mechanism in mice but insufficient for human use. People with fatty liver disease should continue following established medical advice: maintain a healthy weight, reduce refined carbohydrates and saturated fats, exercise regularly, and work with their healthcare provider. Future human clinical trials will determine whether IPA supplementation becomes a viable treatment option.
This research is most relevant to: (1) people with metabolic dysfunction-associated steatotic liver disease (MASLD) or fatty liver disease, (2) researchers studying gut-liver interactions, (3) pharmaceutical companies developing new liver disease treatments, and (4) gastroenterologists and hepatologists treating liver disease. People interested in gut health and microbiome science should also find this relevant. However, people should not self-treat with IPA supplements based on this research alone.
If IPA-based treatments move forward, the timeline would be: 1-2 years for initial human safety studies, 3-5 years for efficacy trials, and potentially 5-10 years before FDA approval and availability as a medication. This is a realistic timeline for drug development. In the meantime, people with fatty liver disease should focus on proven interventions like weight loss and dietary changes.
Frequently Asked Questions
What is IPA and how does it help with fatty liver disease?
IPA (indole-3-propionic acid) is a compound naturally made by gut bacteria. According to 2026 research, IPA protects liver cells by activating a protein called FMO2, which blocks a harmful stress pathway that damages liver cells. In mice, IPA supplementation reduced liver fat and improved insulin resistance.
Can I take IPA supplements now to treat my fatty liver?
Not yet. This research is still in early stages using mice and laboratory cells. Human clinical trials are needed to confirm safety and effectiveness before IPA supplements can be recommended as a medical treatment. Talk to your doctor about proven approaches like weight loss and dietary changes.
How can I naturally increase IPA production in my gut?
Eat more prebiotic foods like asparagus, garlic, onions, and bananas that feed beneficial gut bacteria. Maintain a healthy diet rich in fiber, exercise regularly, and avoid excessive antibiotics when possible. These habits support the gut bacteria that naturally produce IPA.
Is this research applicable to humans with fatty liver disease?
The findings are promising but preliminary. All experiments used mice and liver cells in dishes, not humans. While the biological mechanism appears sound, human studies are needed to determine if IPA supplementation is safe and effective for people with fatty liver disease.
What is endoplasmic reticulum stress and why does it matter?
Endoplasmic reticulum (ER) stress is when a cell’s protein-making machinery becomes overwhelmed and malfunctions, triggering cell death. In fatty liver disease, ER stress damages liver cells. IPA reduces ER stress by blocking a specific signaling pathway, protecting liver cells from damage and death.
Want to Apply This Research?
- Track daily dietary fiber intake (target: 25-30 grams) and weekly exercise minutes (target: 150 minutes moderate activity), as these support healthy gut bacteria that naturally produce IPA. Monitor weight and waist circumference monthly as indicators of metabolic improvement.
- Users could set reminders to increase prebiotic foods (asparagus, garlic, onions, bananas) that feed beneficial gut bacteria, potentially supporting natural IPA production. Log meals and exercise to identify patterns that improve liver health markers.
- Establish a baseline of current diet quality and activity level, then track changes monthly. Users should note energy levels, digestion quality, and any changes in liver-related symptoms (fatigue, abdominal discomfort) as indirect indicators of improvement. Encourage regular check-ins with healthcare providers for liver function tests.
This research describes early-stage laboratory findings in mice and cell cultures. It does not represent approved medical treatment for humans. Indole-3-propionic acid (IPA) is not currently available as a prescription medication or approved supplement for fatty liver disease. Anyone with fatty liver disease or metabolic dysfunction-associated steatotic liver disease (MASLD) should consult with their healthcare provider about evidence-based treatment options, which currently include weight management, dietary modifications, exercise, and in some cases, medications like GLP-1 agonists. Do not self-treat with IPA supplements or other products based on this research. Human clinical trials are necessary before any new treatment can be recommended.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.